Aug. 5 at 8:48 PM
$SUPN
🚨
Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024.
Net sales of Qelbree of
$77.6 million and
$142.3 million in the second quarter and first six months of 2025, respectively.
Net sales of GOCOVRI of
$36.7 million and
$67.4 million in the second quarter and first six months of 2025, respectively.
Total revenues were
$165.5 million and
$315.3 million for the three and six months ended June 30, 2025.
Operating income of
$12.1 million and
$1.9 million for the three and six months ended June 30, 2025, respectively.
Adjusted operating earnings (non-GAAP)(1) were
$40.9 million and
$66.9 million for the three and six months ended June 30, 2025, respectively.
Completed acquisition of Sage Therapeutics, Inc. (Sage) on July 31, 2025.
Increasing full year 2025 revenue guidance and updating full year 2025 operating earnings (loss) guidance to reflect strong first-half 2025 performance and the Sage acquisition.
